Ileana Rebedea *
* Prof. Dr. Ileana Rebedea, Șeful Clinicii de Boli Infecțioase II, UMF “Carol Davila”, medic primar șef de secție Institutul de Boli lnfecțioase “Prof Dr. Matei Balș”, București
Abstract
The incidence of HCV infection has been estimated to be 1 – 3 cases/100.000 persons annually. HCV exists as variants or genotypes resulting from mutations with errors in RNA replication. Acute hepatitis C are moderate, beginning 5 – 12 weeks after infection and marked by fluctuations in ALT concentrations. Acute hepatitis C is the continuation of hepatic inflammation and necrosis, complicated by cirrhosis or primary hepato-cellular carcinoma. The combination of IFN (TIW) plus ribavirin (qd) for 12 months are an optimal treatment of chronic hepatitis C. Pegylated and consensus interferons provides sustained exposure to clinically effective drug levels, enhances efficacy, tolerability and once-weekly dosing may improve compliance. It is presented another antiviral combination in the treatment of HCV infections.